a 69024 has been researched along with Parkinson Disease in 1 studies
*Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gnanalingham, KK; Hunter, AJ; Jenner, P; Marsden, CD | 1 |
1 other study(ies) available for a 69024 and Parkinson Disease
| Article | Year |
|---|---|
Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Callithrix; Dopamine Agonists; Dopamine Antagonists; Male; Models, Neurological; Papaverine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Dopamine D1; Tetrahydroisoquinolines | 1995 |